Filing Details
- Accession Number:
- 0001209191-22-012952
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-24 21:30:48
- Reporting Period:
- 2022-02-22
- Accepted Time:
- 2022-02-24 21:30:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1706431 | Vir Biotechnology Inc. | VIR | Biological Products, (No Disgnostic Substances) (2836) | 812730369 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1786378 | Herbert Virgin | C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158 | Evp, Research & Cso | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-02-22 | 70,000 | $0.00 | 175,407 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2022-02-22 | 1,375 | $1.53 | 176,782 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-22 | 1,375 | $30.00 | 175,407 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-02-22 | 1,375 | $0.00 | 1,375 | $1.53 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-02-22 | 70,000 | $0.00 | 70,000 | $29.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 219,505 | 2028-01-26 | No | 4 | M | Direct | |
| 70,000 | 2032-02-21 | No | 4 | A | Direct |
Footnotes
- Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
- The option is fully vested and exercisable.
- 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
